1. CRISBERT I. CUALTEROS, M.D. Department of Family and Community Medicine Perpetual Succour Hospital

2.

Gerald Holtmann, M.D., Nicholas J. Talley, M.D., Ph.D., Tobias Liebregts, M.D.,

Birgit Adam, M.D., and Christopher Parow, M.D.

New England Journal of Medicine

February 23,2006; 354: page 832-840

3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. A positive response: improvement by at least one grade 15. 16. 17. 18. 19.

Improved symptom-severity scores on the LDQ from baseline in all four study groups.

Itopride was significantly superior to placebo during the testing of the global hypothesis

Placebo and itopride given at 50 mg TID was not significant (P 0.07)

Placebo & itopride at 100 mg TID &

at 200 mg TID were both significant (P 0.05)

20.

Testing of all planned hypotheses for response rates to patients global assessment of efficacy showed significant result

There was a significant association between the dose of itopride and the response rate

The global hypothesis on the response rates according to the severity of pain and fullness yielded a significant discrimination between itopride & placebo

21. Holtmann G et al. N Engl J Med 2006;354:832-840 Response Rates Based on Patients' Global Assessment of Efficacy 22.

NDI quality-of life scores were better among patients treated with active medication than placebo.

The NDI quality-of-life score improved by a mean of 13.2+/-19.4 with placebo and by 18.0+/-21.9 with itopride (P = 0.02).

However, differences between the various doses of itopride tested were not statistically significant.

23. Primary Outcome Variables among 523 Patients 24. 25. 26.

Thank you